LSK Global PS Expanding Use of Medidata Platform

June 15, 2016

LSK Global PS Adopts Medidata’s Clinical Trial Management Solution for Worldwide Operational Efficiency and Project Oversight

  NEW YORK, N.Y. and SEOUL, KOREA – Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences, and LSK Global Pharma Services (“LSK Global PS”), a leading contract research organization (CRO) in South Korea, today announced that LSK Global PS has expanded its use of the Medidata Clinical Cloud platform. The Seoul-based organization is the first Korean company to prioritize its global operational efficiencies and decision-making processes by implementing Medidata CTMS-further demonstrating its traction in the growing Asia-Pacific market and beyond.   “LSK Global PS is dedicated to advancing the quality of our domestic clinical trials to that of a global standard, and Medidata’s robust, globally-validated CTMS is helping us reach that standard,” said Young Jack Lee, president of LSK Global PS.   “Medidata CTMS enables us to conduct more efficient clinical research, accelerating study timelines and reducing development costs while ensuring the highest quality. We’re excited to take our drug development program to the next level by using more technology solutions on Medidata’s industry-leading, unified cloud platform to manage clinical trials across therapeutic areas,” Lee added.   Established in 2000, LSK Global PS is a full-service CRO conducting hundreds of clinical trial programs on both a local and global scale. Specializing in a number of therapeutic areas-including oncology, cardiovascular and endocrinology, among others-LSK Global PS conducts Phase I-Phase IV studies, investigator initiated trials, post-market surveillance (PMS), and observational research, and provides data management services for its life sciences customers.   LSK Global PS has been utilizing Medidata’s electronic data capture, management and reporting tool (Medidata Rave®), medical coding solution (Medidata Coder®), and unified randomization and trial supply management solution (Medidata Balance®). To provide better oversight into trial operations and streamline its site monitoring processes, the CRO is now adopting Medidata’s clinical trial management system, Medidata CTMS.   “As South Korea continues to evolve as a key market in Asia’s expanding clinical trial landscape, we’re pleased to be strengthening our partnership with LSK Global PS,” said Edwin Ng, Medidata’s vice president of field operations, APeJ (Asia Pacific except Japan). “By leveraging CTMS’ customized reporting capabilities-powered by its seamless integration with Rave-LSK Global PS is able to extract the operational data it needs to effectively deploy critical resources, proactively address performance issues and streamline study workflows. We look forward to our ongoing collaboration with LSK, providing its research teams with the technology needed to accelerate medical innovation across the region and beyond.”

Related Content:

News